Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Buy
57
MIRA Quote, Financials, Valuation and Earnings
Last price:
$1.47
Seasonality move
:
-29.55%
Day range:
$1.44 - $1.50
52-week range:
$0.73 - $2.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
8.10x
Volume:
160.1K
Avg. volume:
350.8K
1-year change:
22.69%
Market cap:
$61.1M
Revenue:
--
EPS (TTM):
-$1.52
Analysts' Opinion
-
Consensus RatingMIRA Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $10.38, MIRA Pharmaceuticals, Inc. has an estimated upside of 610.62% from its current price of $1.46.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 100% downside risk from its current price of $1.46.
Fair Value
-
According to the consensus of 1 analyst, MIRA Pharmaceuticals, Inc. has 610.62% upside to fair value with a price target of $10.38 per share.
MIRA vs. S&P 500
-
Over the past 5 trading days, MIRA Pharmaceuticals, Inc. has underperformed the S&P 500 by -1.66% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
MIRA Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
MIRA Pharmaceuticals, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter MIRA Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
MIRA Pharmaceuticals, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter MIRA Pharmaceuticals, Inc. reported earnings per share of -$1.18.
Enterprise value:
53.6M
EV / Invested capital:
7.10x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-10.05x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-831.28%
Net Income Margin (TTM):
--
Return On Equity:
-935.53%
Return On Invested Capital:
-935.53%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$7.3M | -$8.6M | -$7.1M | -$2.1M | -$1.3M | |
| EBITDA | -$7.3M | -$8.6M | -$7.1M | -$2.1M | -$1.3M | |
| Diluted EPS | -$0.54 | -$0.73 | -$1.52 | -$0.14 | -$1.18 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $6.1M | $4.2M | $7.6M | |
| Total Assets | -- | -- | $9M | $4.3M | $7.6M | |
| Current Liabilities | -- | -- | $868.4K | $692.8K | $83.9K | |
| Total Liabilities | -- | -- | $902.9K | $692.8K | $83.9K | |
| Total Equity | -- | -- | $8.1M | $3.6M | $7.5M | |
| Total Debt | -- | -- | $34.5K | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$4.5M | -$5.9M | -$5.3M | -$1.8M | -$1.1M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $10.2M | $4.2M | $3.8M | $3.2M | $3M | |
| Free Cash Flow | -$4.5M | -$5.9M | -$5.3M | -$1.8M | -$1.1M | |
MIRA
Sector
Market Cap
$61.1M
$28.5M
Price % of 52-Week High
59.59%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-7.1%
-1.33%
1-Year Price Total Return
22.69%
-20.32%
Beta (5-Year)
--
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.45
200-day SMA
Buy
Level
$1.31
Bollinger Bands (100)
Sell
Level
1.32 - 1.62
Chaikin Money Flow
Sell
Level
-77M
20-day SMA
Buy
Level
$1.42
Relative Strength Index (RSI14)
Buy
Level
51.06
ADX Line
Buy
Level
15.74
Williams %R
Neutral
Level
-21.0526
50-day SMA
Buy
Level
$1.45
MACD (12, 26)
Buy
Level
0.03
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
154.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.4579)
Sell
CA Score
(Annual)
Level (-8.1221)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (6)
Sell
Ohlson Score
Level (25.3549)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. It engages in developing its product candidates, Ketamir-2 and MIRA-55, designed to address unmet medical needs in pain management, depression, PTSD, and cognitive function. The company was founded by Adam Kaplin on September 3, 2020 and is headquartered in Miami, FL.
Stock Forecast FAQ
In the current month, MIRA has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MIRA average analyst price target in the past 3 months is $10.38.
-
Where Will MIRA Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that MIRA Pharmaceuticals, Inc. share price will rise to $10.38 per share over the next 12 months.
-
What Do Analysts Say About MIRA Pharmaceuticals, Inc.?
Analysts are divided on their view about MIRA Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that MIRA Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is MIRA Pharmaceuticals, Inc.'s Price Target?
The price target for MIRA Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $10.38 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MIRA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for MIRA Pharmaceuticals, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of MIRA?
You can purchase shares of MIRA Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase MIRA Pharmaceuticals, Inc. shares.
-
What Is The MIRA Pharmaceuticals, Inc. Share Price Today?
MIRA Pharmaceuticals, Inc. was last trading at $1.47 per share. This represents the most recent stock quote for MIRA Pharmaceuticals, Inc.. Yesterday, MIRA Pharmaceuticals, Inc. closed at $1.46 per share.
-
How To Buy MIRA Pharmaceuticals, Inc. Stock Online?
In order to purchase MIRA Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get MIRA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MIRA
Sector
P/E ratio
--
23.75x
PEG ratio
-0.01x
-0.01x
P/B ratio
8.10x
1.83x
Price / LTM sales
--
1.60x
Growth Metrics
MIRA
Sector
Revenue growth
--
4.85%
Earnings growth
-768.29%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.08
-$0.20
Profitability
MIRA
Sector
Profitability FY 2024
--
$3.6M
Return on invested capital
-935.53%
-30.98%
Return on assets
-831.28%
-27.62%
Return on equity
-935.53%
-36.69%
Earnings Date
Last Earnings Date
Dec
6
Next Earnings Date
Dec
6
Estimated Next Earnings Date
Mar
7
Balance Sheet
MIRA
Sector
Total cash
$7.5M
$27.2M
Short term investments
--
$25.7M
Total assets
$2.9M
$79.7M
Long term debt
--
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
